Axsome Therapeutics (AXSM) EBITDA (2015 - 2026)
Axsome Therapeutics recorded quarterly EBITDA of -$63.4 million in Q1 2026, down 162.53% quarter-over-quarter from $101.3 million in Q4 2025, and down 11.19% year-over-year from -$71.3 million in Q1 2025.
Axsome Therapeutics' EBITDA history runs 12 years deep, the most recent figure standing at -$63.4 million for Q1 2026.
- In Q1 2026, EBITDA fell 11.19% year-over-year to -$63.4 million; the TTM figure through Mar 2026 stood at -$44.9 million (up 83.4% YoY), while the FY2025 annual figure was -$38.5 million, up 86.29% from the prior year.
- EBITDA came in at -$63.4 million for Q1 2026 at Axsome Therapeutics, down from $101.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $101.3 million in Q4 2025 to a low of -$98.3 million in Q4 2023.
- A 5-year average of -$46.7 million and a median of -$59.9 million in 2022 frame the typical range for EBITDA.
- Across the five-year window, EBITDA slumped 955.46% in 2024 and jumped 239.53% in 2025, its largest moves.
- Axsome Therapeutics' EBITDA stood at -$59.9 million in 2022, then tumbled by 64.01% to -$98.3 million in 2023, then climbed by 26.11% to -$72.6 million in 2024, then surged by 239.53% to $101.3 million in 2025, then tumbled by 162.53% to -$63.4 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$63.4 million, $101.3 million, and -$46.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -63.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.36 Mn |
| Dec 31, 2025 | 101.33 Mn |
| Sep 30, 2025 | -46.11 Mn |
| Jun 30, 2025 | -36.71 Mn |
| Mar 31, 2025 | -56.98 Mn |
| Dec 31, 2024 | -72.62 Mn |
| Sep 30, 2024 | -62.62 Mn |
| Jun 30, 2024 | -78.05 Mn |
| Mar 31, 2024 | -67.28 Mn |
| Dec 31, 2023 | -98.27 Mn |
| Sep 30, 2023 | -62.12 Mn |
| Jun 30, 2023 | -65.06 Mn |
| Mar 31, 2023 | -6.37 Mn |
| Dec 31, 2022 | -59.92 Mn |
| Sep 30, 2022 | -42.41 Mn |
| Jun 30, 2022 | -39.18 Mn |
| Mar 31, 2022 | -38.29 Mn |
| Dec 31, 2021 | -32.61 Mn |
| Sep 30, 2021 | -33.41 Mn |
| Jun 30, 2021 | -30.85 Mn |
| Mar 31, 2021 | -27.84 Mn |
| Dec 31, 2020 | -27.74 Mn |
| Sep 30, 2020 | -21.13 Mn |
| Jun 30, 2020 | -17.78 Mn |
| Mar 31, 2020 | -32.49 Mn |
| Dec 31, 2019 | -24.43 Mn |
| Sep 30, 2019 | -18.95 Mn |
| Jun 30, 2019 | -13.45 Mn |
| Mar 31, 2019 | -10.42 Mn |
| Dec 31, 2018 | 9.45 Mn |
| Sep 30, 2018 | -8.24 Mn |
| Jun 30, 2018 | -7.99 Mn |
| Mar 31, 2018 | -7.16 Mn |
| Dec 31, 2017 | 6.44 Mn |
| Sep 30, 2017 | 6.30 Mn |
| Jun 30, 2017 | 6.75 Mn |
| Mar 31, 2017 | 7.67 Mn |
| Dec 31, 2016 | 7.63 Mn |
| Sep 30, 2016 | 7.21 Mn |
| Jun 30, 2016 | 6.83 Mn |
| Mar 31, 2016 | 5.88 Mn |
| Dec 31, 2015 | 3.15 Mn |
| Sep 30, 2015 | 2.02 Mn |
| Jun 30, 2015 | 2.08 Mn |
| Mar 31, 2015 | 1.93 Mn |